JAB BX 102
Alternative Names: JAB-BX102Latest Information Update: 24 Mar 2023
At a glance
- Originator Jacobio Pharmaceuticals
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action 5-nucleotidase inhibitors; Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 22 Mar 2023 Jacobio Pharma enter into a clinical collaboration with Merck to evaluate JAB BX 102 for the treatment of Solid tumors
- 22 Mar 2023 Jacobio Pharma and Merck plan a clinical trial in Solid tumors (Combination therapy)
- 02 Sep 2022 Phase-I/II clinical trials in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (IV) (NCT05174585)